Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…

Read More

Oncology Letters 2021 February [Link] Vincenzo Fontana, Maria Pia Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Paolo Dessanti, Silvio Roncella Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting…

Read More

Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…

Read More

The Lancet Respiratory Medicine 2021 January 27 [Link] Dean A Fennell, Amy King, Seid Mohammed, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Adrian Nicholson, Cathy Richards, Peter Wells-Jordan, Gavin James Murphy, Anne Thomas Abstract Background: Malignant mesothelioma remains an incurable cancer, with no effective treatments in the…

Read More

Clinical Chemistry 2020 December 18 [Link] Kai Bartkowiak, Swaantje Casjens, Antje Andreas, Lucija Ačkar, Simon A Joosse, Irina Raiko, Thomas Brüning, Maria Geffken, Sven Peine, Georg Johnen, Daniel Gilbert Weber, Klaus Pantel Abstract Background: Detection of asbestos-associated diseases like asbestosis or mesothelioma is still challenging. We sought to improve the diagnosis of benign asbestos-associated disease…

Read More

Pathology 2020 November 30 [Link] Eltjona Rrapaj, Lorenzo Giacometti, Paolo Spina, Michela Salvo, Guido Alessandro Baselli, Claudia Veggiani, Ottavio Rena, Elena Trisolini, Renzo Luciano Boldorini Abstract Malignant pleural mesothelioma (MPM) is often associated with a poor prognosis and options for the treatment of this disease are few. To date, the important role of the immune…

Read More

Environmental Research 2020 November 13 [Link] Hailing Xia, Lingfang Feng, Lijun Lin, Zhaoqiang Jiang, Junqiang Chen, Wei Shi, Shibo Ying, Min Yu, Li Ju, Lijin Zhu, Li Shi, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive cancer linked to asbestos exposure. Its poor prognosis makes early diagnosis extremely important, which would provide…

Read More

EBioMedicine 2020 October 9 [Link] Bill T V Duong, Licun Wu, Brenda J Green, Fatemeh Bavaghar-Zaeimi, Zongjie Wang, Mahmoud Labib, Yuxiao Zhou, Fernando J P Cantu, Thurgaa Jeganathan, Sandra Popescu, Jennifer Pantea, Marc de Perrot, Shana O Kelley Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer related to asbestos exposure. Early diagnosis is…

Read More

Pharmaceuticals 2020 October 2 [Link] Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Diana Cao, Ingrid J G Burvenich, Angela Rigopoulos, Edward B Reilly, Thomas John, Andrew M Scott Abstract Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a…

Read More

Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…

Read More